Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
Prof. Thierry FACON, Prof. Mchel DELFORGE, and Prof. Mohamad MOHTY
November 23, 2021
source